Improving Diabetes Outcomes for People With Severe Mental Illness (SMI)

NCT ID: NCT03534921

Last Updated: 2020-03-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46564 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-01

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to identify the determinants of diabetes and to explore variation in diabetes outcomes for people with severe mental illness (schizophrenia, schizoaffective disorder and bipolar disorder) in order to develop potential healthcare interventions that can be tested further.

The study utilises a mixed methods design comprising analysis of patient primary care records and interviews with patients living with comorbid SMI and diabetes, family carers and healthcare professionals involved in commissioning or delivering healthcare for this population. This entry on the Protocol Registration and Results System describes only the quantitative Work Package of the study in detail i.e. analysis of patient primary care records.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

People living with severe mental illness (SMI) have a lower life expectancy (by around 20 years) than the general population, often dying of preventable or manageable illnesses (Woodhead et al., 2014). Diabetes contributes significantly to this health inequality, being 2-3 times more likely in people with SMI (Stubbs et al., 2015). This study aims to understand the determinants of type 2 diabetes and variation in diabetes outcomes for people with SMI in order to identify potential healthcare interventions that can be tested further.

Research questions:

1. What are the socio-demographic and illness-related risk factors associated with

1. developing type 2 diabetes in people with SMI?
2. variation in diabetes and mental health outcomes in people with SMI and type 2 diabetes?
2. How do physical and mental health outcomes differ between people with SMI and type 2 diabetes,

1. compared to people with SMI without diabetes?
2. compared to people with type 2 diabetes but no SMI?
3. What factors influence access to, and receipt of, diabetes care for people with SMI, and how are diabetes healthcare interventions experienced by people with SMI?
4. How and at what cost is type 2 diabetes monitored and managed in people with SMI compared to those without SMI?
5. What healthcare interventions (e.g. medication, referrals and care pathways) are associated with better diabetes outcomes for people with SMI and type 2 diabetes?

The study has the following objectives:

1. In people with SMI, to identify which socio-demographic, illness, family history and lifestyle factors are associated with the development of type 2 diabetes.
2. In people with SMI and type 2 diabetes, to identify which socio-demographic, illness, family history and lifestyle factors are associated with variation in diabetes and mental health outcomes.
3. In people with SMI, to compare healthcare interventions, physical and mental health outcomes in those with type 2 diabetes with those without diabetes.
4. In people with type 2 diabetes, to compare healthcare interventions, physical and mental health outcomes in those with SMI and those without SMI.
5. To understand the factors that influence access to, and receipt of, diabetes care for people with SMI, and explore the experience of diabetes healthcare by people with SMI.
6. To compare diabetes care provision for people with and without SMI, and estimate costs for these.
7. To identify which healthcare interventions (e.g. medication, referrals and care pathways) may be associated with better diabetes outcomes for people with SMI and type 2 diabetes.

Study design:

The study will utilise a convergent triangulation mixed methods design comprising a quantitative longitudinal observational study of individual patient records of adults with diagnosed SMI and diabetes held in the Clinical Practice Research Datalink (CPRD, a computerised database of anonymised primary care medical records drawn from a proportion of general practices in the UK) with qualitative interviews with patients, their family carers and healthcare professionals who commission or deliver services to this comorbid population. This entry on the Protocol Registration and Results System describes only the quantitative work stream of the study i.e. the interrogation of patient primary care records. The key healthcare outcomes to be examined are listed; however, a definitive list of outcomes will be agreed through a consensus process with project team members.

The complete study is organised in three work packages:

1. Work Package One, which involves ongoing consultation with experts (service users and family members belonging to a Patient and Public Involvement (PPI) panel, healthcare staff and researchers) to refine questions and analyses, a synthesis of evidence on SMI and diabetes risks and outcomes, integrating the qualitative and quantitative studies, conducting co-design workshops to translate study findings into recommendations, and optimising the dissemination of findings.
2. Work Package Two, which investigates the role of risk factors thought to influence i) development of type 2 diabetes in people with SMI (objective 1), and ii) variation in health outcomes in people with comorbid SMI and type 2 diabetes (objective 2). Further analyses involve a comparison of diabetes healthcare and outcomes for people with SMI and type 2 diabetes with outcomes for people with either condition alone (objectives 3 and 4), an examination of variations in type 2 diabetes screening, monitoring and management and estimation of the costs for these (objective 6); and an exploration of the role of these interventions in contributing to health outcomes (objective 7). These investigations will utilise the CPRD database, which is linked to other datasets, including Hospital Episode Statistics (HES) data, HES-Office of National Statistics mortality data, and Index of Multiple Deprivation (IMD) data.

Three CPRD datasets will be analysed which will consist of linked records from the study period of 01 April 2000 to 31 March 2016. The first of these, Dataset A, will contain records of a cohort of adult patients with a diagnosis of SMI. Dataset B is constructed from Dataset A, and comprises those in Dataset A who also have a diagnosis of diabetes. Finally, Dataset C is a cohort of patients with diabetes but no record of SMI who are age and gender-matched to Dataset B on a ratio of 4:1.
3. Work Package Three, which explores the experience of diabetes management and healthcare from three perspectives: patients, family members or friends who support them and healthcare professionals who commission or deliver services.

Dissemination

Findings will be translated into service recommendations through two multi-stakeholder co-design workshops. The first of these will identify further avenues of inquiry for the final stages of analysis and will develop draft recommendations to improve the organisation and delivery of healthcare for this comorbid population. The second workshop will further develop the recommendations based on the final analyses and will design interventions or care pathways, assessing their potential acceptability and feasibility for future evaluation and implementation.

A dissemination event will be held, presenting materials in a range of formats to maximise opportunities for knowledge exchange. Study outputs will include a final report for the funding body, scientific papers submitted to international peer-reviewed journals, short articles in practitioner journals, executive summaries published on websites, conference presentations, and other materials disseminated through clinical, academic and voluntary sector networks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Severe Mental Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

People with severe mental illness (SMI)

In the study period 01/04/2000-31/03/2016, people with records on the Clinical Practice Research Datalink aged \>=18 years with a record of severe mental illness so that at least one event occurs in the study period.

No interventions assigned to this group

People with SMI and type 2 diabetes

Drawn from the first cohort, this group also has a record of type two diabetes mellitus registered during the study period.

No interventions assigned to this group

People with diabetes (matched controls)

This cohort will be matched on a 4:1 ratio by age (+- 2 years), gender and general practitioner practice to the group of people with comorbid SMI and diabetes.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 and over
* Patients with diagnoses of severe mental illness, severe mental illness and type 2 diabetes, or with diabetes but no diagnosis of severe mental illness.
* Patients with research-quality data.

Exclusion Criteria

* Patients under the age of 18
* Patients without research quality data.
* Patients who were diagnosed with Type 1 diabetes following a diagnosis of Type 2 diabetes.
* Patients who have a code for a diabetic complication (e.g. diabetic retinopathy) but no diagnostic code for diabetes.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Leeds

OTHER

Sponsor Role collaborator

University of Southampton

OTHER

Sponsor Role collaborator

University of York

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Najma Siddiqi

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr Siddiqi

Role: PRINCIPAL_INVESTIGATOR

University of York

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of York

York, Yorkshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Woodhead C, Ashworth M, Schofield P, Henderson M. Patterns of physical co-/multi-morbidity among patients with serious mental illness: a London borough-based cross-sectional study. BMC Fam Pract. 2014 Jun 11;15:117. doi: 10.1186/1471-2296-15-117.

Reference Type BACKGROUND
PMID: 24919453 (View on PubMed)

Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015 Aug;132(2):144-57. doi: 10.1111/acps.12439. Epub 2015 May 5.

Reference Type BACKGROUND
PMID: 25943829 (View on PubMed)

Bellass S, Taylor J, Han L, Prady SL, Shiers D, Jacobs R, Holt RIG, Radford J, Gilbody S, Hewitt C, Doran T, Alderson SL, Siddiqi N. Exploring Severe Mental Illness and Diabetes: Protocol for a Longitudinal, Observational, and Qualitative Mixed Methods Study. JMIR Res Protoc. 2019 Sep 6;8(9):13407. doi: 10.2196/13407.

Reference Type DERIVED
PMID: 31493324 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15/70/26

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bipolar Disorder Study for Men and Women
NCT00056277 COMPLETED PHASE3